For several years "ischemic" electrocardiographic (ECG) changes in the acute phase of ischemic stroke have been reported. Whether these ECG changes reflect true myocardial ischemia remains controversial. So far no study has assessed different markers of myocardial ischemia or necrosis in consecutive patients admitted to hospital with an acute ischemic stroke.
The main purpose of this study is to determine the potential burden of reversible and irreversible myocardial ischemia in patients with an acute ischemic stroke.
Patients and methods
Serial blood samples for measuring troponin T, CK-MB and NT-proBNP are collected in 250 patients with evidence of an acute ischemic stroke admitted to the Department of Neurology at Odense University Hospital. In addition resting 12-lead ECG recordings will be obtained on a daily basis, and a 24-hour ST-segment ambulatory monitoring will be performed once within the first week of hospitalisation. Finally, myocardial perfusion patterns during rest will be evaluated by means of a myocardial perfusion scintigraphy in patients with an elevated troponin T level.
Six months later control measurements of troponin T, CK-MB and NT-proBNP and a 12-lead ECG will be obtained.
The study will contribute with original observations in patients with acute ischemic stroke considering the following issues:
1. The prevalence and characteristics of ECG changes suggestive of myocardial ischemia.
2. The prevalence of transient ST-segment changes on ambulatory monitoring.
3. The prevalence and degree of myocardial necrosis as judged from biochemical markers.
4. The prevalence of reversible and irreversible perfusion defects on myocardial scintigraphy.
5. The prevalence, size and patterns of NT-proBNP.
6. Whether there is a change in ECG and biochemical markers over a 6-month follow-up period.
The results may have clinical implications regarding early and late treatment as well as clinical follow-up of patients recovering from an episode of acute ischemic stroke.
- Purpose: Screening
- Observation: Defined Population
- Perspective: Prospective
|Type||Measure||Time Frame||Safety Issue|
|No outcomes associated with this trial.|
- Danish Heart Foundation Lead
- Novo Nordisk
- Odense University Hospital
- Raimond og Dagmar Ringgård Bohns Fond
- AJ Andersen og Hustrus Fond
- Novo Nordisk A/S
- Raimond and Dagmar Ringgård-Bohn's Foundation
- Bankdirektør Hans Stener og hustru Agnes Steners legat
- Overlægerådet Legatudvalg
- Fonden for Lægevidenskabelig Forskning for Fyns Amt.